In the current study, we performed RNA-seq and bioinformatic analyses to identify additional genes and pathways that are up- or downregulated as a result of Dox-inducible CD133 expression in melanoma cells that could reveal actionable targets for drug-resistant MM. The gene discussed is PROM1; the disease is Miyoshi myopathy.